

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB1 gene) or a gene product thereof.
2. (original) The human protein according to claim 1, which is a polypeptide or protein selected from a group consisting of: (1) a polypeptide or protein represented by an amino acid sequence set forth in SEQ ID No: 1 in the sequence listing; (2) a polypeptide containing an amino acid sequence comprising at least five amino acids of the amino acid sequence of the polypeptide or protein; (3) a polypeptide or protein having homology of at least approximately 70% at the amino acid sequence level with the polypeptide or protein; and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the polypeptide or protein according to any one of the preceding (1) to (3).
3. (original) The animal protein according to claim 1 that is a protein derived from mouse, and which is a polypeptide or protein selected from the group consisting of: (1) a polypeptide or protein represented by an amino acid sequence set forth in SEQ ID No: 2 in the sequence listing; (2) a polypeptide containing an amino acid sequence comprising at least five amino acids of the amino acid sequence of the polypeptide or protein; (3) a polypeptide or protein having homology

of at least approximately 70% at the amino acid sequence level with the polypeptide or protein;
and (4) a protein or polypeptide having a mutation or induced mutation such as a deletion, substitution or addition of one to several amino acids relative to the amino acid sequence of the polypeptide or protein according to any one of the preceding (1) to (3).

4. (currently amended) A nucleic acid coding for the polypeptide or protein according to ~~any one of claims 1 to 3~~ claim 1, or a complementary strand thereof.

5. (original) A nucleic acid hybridizing under stringent conditions with the nucleic acid according to claim 3 or the complementary strand thereof.

6. (currently amended) A nucleic acid represented by a base sequence comprising at least 15 consecutive bases of the base sequence of a nucleic acid set forth in SEQ ID Nos: 3 to 4 in the sequence listing or a complementary strand thereof, wherein a polypeptide expressed by transcription of the nucleic acid is the polypeptide according to ~~any one of claims 1 to 3~~ claim 1.

7. (currently amended) A recombinant vector containing the nucleic acid according to ~~any one of claims 4 to 6~~ claim 4.

8. (original) A transformant that was transformed with the recombinant vector according to claim 7.

9. (currently amended) A method for producing the polypeptide or protein according to ~~any one of claims 1 to 3~~ claim 1, comprising a step of culturing the transformant with the recombinant vector containing nucleic acid coding for the polypeptide or protein according to claim 8.

10. (currently amended) Nucleic acid primers set forth in SEQ ID Nos: 5 to 132 in the sequence listing, which hybridize under stringent conditions with the nucleic acid according to ~~any one of claims 4 to 6~~ claim 4 or the complementary strand thereof.

11. (currently amended) An antibody that immunologically recognizes the polypeptide or protein according to ~~any one of claims 1 to 3~~ claim 1.

12. (currently amended) A method of screening for compounds that inhibit or enhance a function that can induce transcription factor activity and/or expression of RB1 gene of the polypeptide or protein according to ~~any of claims 1 to 3~~ claim 1, wherein the method utilizes ~~uses~~ at least one member of the group consisting of the polypeptide, or the protein, or an antibody that immunologically recognizes the polypeptide or protein according to any one of claims 1 to 3 and the antibody according to claim 11.

13. (currently amended) A method of screening for compounds that interact with the nucleic acid according to ~~claim 4 or 6~~ to inhibit or enhance expression of the nucleic acid, wherein the method utilizes ~~uses~~ at least one member of the group consisting of the nucleic acid according to any one claims 4 to 6, the, a recombinant vector containing the nucleic acid according to claim 7,

~~the, a transformant that was transformed with the recombinant vector according to claim 8, and~~
~~the or nucleic acid primers set forth in SEQ ID NOS: 5 to 132 in the sequence listing which~~
~~hybridize under stringent conditions with the nucleic acid according to claim 10.~~

14. (currently amended) A compound that was screened by the screening method according to
claim 12 ~~or 13~~.

15. (currently amended) A compound that inhibits or enhances transcription factor activity
and/or a function that can induce expression of RB1 gene of the polypeptide or protein according
to ~~any of claims 1 to 3~~ claim 1.

16. (currently amended) A compound that interacts with the nucleic acid according to ~~any one~~
~~of claims 4 to 6~~ claim 4 to inhibit or enhance expression of the nucleic acid.

17. (currently amended) A pharmaceutical composition for use in treatment of multidrug
resistance that is resistance to treatment with anticancer agents, wherein the pharmaceutical
composition comprises ~~at least one member of the group consisting of~~ the polypeptide or protein
according to ~~any of claims 1 to 3~~ claim 1, ~~the, a nucleic acid coding for the polypeptide or protein~~
~~or a complementary strand thereof according to any one of claims 4 to 6, the, a recombinant~~
~~vector containing the nucleic acid according to claim 7, the, a transformant that was transformed~~
~~with the recombinant vector according to claim 8, the, nucleic acid primers set forth in SEQ ID~~
~~NOS: 5 to 132 in the sequence listing which hybridize under stringent conditions with the nucleic~~
~~acid according to claim 10, the, an antibody that immunologically recognizes the polypeptide or~~

~~protein according to claim 11, and the~~ or a compound that interacts with nucleic acid to inhibit or enhance expression of the nucleic acid according to any one of claims 14 to 16.

18. (currently amended) A method of testing and diagnosing a disease related with expression or activity of the polypeptide or protein according to ~~any of claims 1 to 3~~ claim 1, wherein the method comprises a step of conducting analysis employing (a) a nucleic acid encoding the polypeptide or protein and/or (b) the polypeptide or protein, as a marker in a sample.

19. (original) The method of testing and diagnosing according to claim 18, which is a method of testing cancer cells or a method for diagnosing a cancer.

20. (currently amended) The method according to claim 18 ~~or 19~~ which detects expression, increase, decrease, lack or the like of all or a part of the polypeptide or protein ~~according to any of claims 1 to 3~~, wherein the method utilizes ~~uses the~~ an antibody that immunologically recognizes the polypeptide according to claim 11.

21. (currently amended) The method according to claim 18 ~~or 19~~ which detects expression, mutation, lack or insertion or the like of all or a part of a gene encoding the polypeptide or protein ~~according to any of claims 1 to 3~~ through a step of amplifying a gene encoding the polypeptide or protein ~~according to any of claims 1 to 3~~ using utilizing at least one of nucleic acid primers set forth in SEQ ID NOS: 5 to 132 in the sequence listing, which hybridize under stringent conditions with the nucleic acid according to claim 10.

22. (currently amended) The method according to ~~any of claims 18 to 21~~ claim 18, wherein the method combines assay of expression, increase, decrease, mutation, lack or insertion or the like of all or a part of tumor-suppressor gene retinoblastoma gene (RB1 gene) or the gene product thereof (RB1 protein).

23. (currently amended) The method according to ~~any of claims 18 to 22~~ claim 18, wherein the method combines assay of expression, increase, decrease, mutation, lack or insertion or the like of all or a part of multidrug resistance gene (MDR1 gene) or the gene product thereof (MDR1 protein: P-glycoprotein).

24. (currently amended) The method according to ~~any of claims 18 to 23~~ claim 18, wherein the method combines assay of expression, increase, or decrease or the like of all or a part of the cell proliferation marker, Ki-67 protein.

25. (original) A method that tests drug sensitivity of a cancer cell using the method according to claim 23.

26. (currently amended) A kit and a reagent for assay or diagnosis, for use in the method according to ~~any of claim 18 to 25~~.